Sanofi (NASDAQ:SNY) Receives $55.00 Consensus PT from Analysts

Sanofi (NASDAQ:SNYGet Free Report) has been given a consensus recommendation of “Hold” by the five ratings firms that are covering the company, reports. Three analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $55.00.

SNY has been the topic of several research analyst reports. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, Morgan Stanley initiated coverage on Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target for the company.

Get Our Latest Stock Analysis on SNY

Sanofi Stock Up 1.9 %

Sanofi stock opened at $50.21 on Friday. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.72. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The firm has a market cap of $127.01 billion, a PE ratio of 25.23, a P/E/G ratio of 1.37 and a beta of 0.61. The firm’s 50 day moving average price is $48.11 and its two-hundred day moving average price is $48.03.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio (DPR) is currently 74.37%.

Institutional Trading of Sanofi

A number of institutional investors and hedge funds have recently made changes to their positions in SNY. Rise Advisors LLC grew its stake in Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares during the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi in the fourth quarter valued at about $27,000. Venturi Wealth Management LLC increased its stake in shares of Sanofi by 163.5% in the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares during the period. Frazier Financial Advisors LLC acquired a new position in shares of Sanofi during the 4th quarter worth about $28,000. Finally, Register Financial Advisors LLC bought a new stake in Sanofi during the 1st quarter valued at approximately $29,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

(Get Free Report

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Read More

Analyst Recommendations for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.